DEF: BioXcel Therapeutics Seeks Reverse Stock Split Authority

BioXcel Therapeutics, Inc. will hold its 2025 Annual Meeting to vote on director elections, auditor ratification, executive compensation, and a proposed reverse stock split to maintain Nasdaq compliance.

Summary

• The Annual Meeting of Stockholders will be held virtually on Friday, December 12, 2025, at 9:00 a.m. Eastern Time, with October 31, 2025, as the record date for voting.
• Key proposals include the election of three Class I directors (June Bray, Sandeep Laumas, M.D., and David Mack) to terms expiring in 2028.
• Stockholders will vote on the ratification of Ernst & Young LLP as the independent registered public accounting firm for 2025.
• An advisory (non-binding) vote on the compensation of named executive officers (Say-on-Pay) is also on the agenda.
• A significant proposal seeks approval for an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio of not less than 1-for-2 and not greater than 1-for-20, to be implemented within 12 months if the Board determines it necessary to regain compliance with Nasdaq's minimum bid price requirements. The company is currently compliant but has faced past deficiencies.
• The Board also seeks authorization for one or more adjournments of the Annual Meeting to solicit additional proxies if there are insufficient votes to approve the reverse stock split proposal.
• Net income for 2024 was $(59.6) million, an improvement from $(179.1) million in 2023 and $(165.8) million in 2022.
• Total Shareholder Return (TSR) for a $100 initial investment declined significantly, from $105.66 in 2022 to $14.51 in 2023, and further to $1.84 in 2024.
• The Board determined not to award annual cash bonuses to named executive officers for 2024 performance, and the company is restricted from paying cash bonuses in 2024 and 2025 without OFA's consent.
• The company completed a registered direct offering in March 2024, raising approximately $24.9 million in net proceeds, and another offering in November 2024 to Armistice.

Sentiment

Score: 3

Explanation: The filing reveals significant financial challenges, including substantial net losses and a drastic decline in TSR over three years. The need for a precautionary reverse stock split and the lack of executive bonuses for 2024 performance underscore operational and financial difficulties. While the company is taking steps to address Nasdaq compliance and has raised capital, the overall picture suggests a company in a precarious position, requiring significant future financing and facing substantial risks.

Positives

• The company is currently in compliance with the Nasdaq Capital Market's minimum bid price requirements.
• The Board is proactively seeking stockholder approval for a reverse stock split as a precautionary measure, providing flexibility to address potential future Nasdaq compliance issues without delay.
• Seven out of eight current directors are independent, indicating a strong commitment to corporate governance.
• The company has adopted a Compensation Recovery Policy (Clawback Policy) in 2023 and maintains an Insider Trading Compliance Policy, aligning with best governance practices.
• Net income improved from a loss of $(179.1) million in 2023 to $(59.6) million in 2024, indicating a reduction in losses.

Negatives

• The necessity of proposing a reverse stock split, even as a precautionary measure, highlights past struggles with Nasdaq minimum bid price requirements and potential future concerns about the stock's valuation.
• Total Shareholder Return (TSR) has experienced a drastic decline over the past three fiscal years, with a $100 investment in 2021 being worth only $1.84 by the end of 2024.
• Executive officers did not receive annual cash bonuses for 2024 performance, and the company is restricted from paying cash bonuses in 2024 and 2025 without OFA's consent, suggesting underperformance or financial constraints.
• Compensation Actually Paid (CAP) for the PEO and Non-PEO NEOs was negative in 2023 and significantly lower in 2024 compared to 2022, reflecting poor financial outcomes for executives.
• Several executive officers and directors had delinquent Section 16(a) reports in April 2024 and April 2025, indicating potential administrative oversight issues.
• The company explicitly states it expects to require additional financing to fund its ongoing activities, signaling potential future dilution for shareholders.

Risks

• **Nasdaq Delisting Risk**: While currently compliant, there is no guarantee the common stock bid price will continue to satisfy Nasdaq Minimum Bid Price Requirements in the future. Delisting would impair the ability to raise additional funds and result in lower prices and larger bid-ask spreads.
• **Negative Perception of Reverse Stock Splits**: Some investors, analysts, and market participants view reverse stock splits negatively, which could adversely affect the market for the common stock.
• **Stock Price Decline Post-Split**: There is no assurance that the total market capitalization will be equal to or greater than before the split, or that the per-share price will increase proportionally. The stock price of some companies that have effected reverse stock splits has subsequently declined.
• **Reduced Liquidity**: A reduced number of shares outstanding after a reverse stock split could adversely affect liquidity.
• **Odd Lot Holders**: The reverse stock split may increase the number of stockholders owning 'odd lots' (less than 100 shares), leading to increased selling costs and difficulty in effecting sales.
• **Loss of Stockholder Status**: Stockholders owning fewer than 2 to 20 shares (depending on the ratio) prior to the split will own less than one share and will receive cash, ceasing to be stockholders.
• **Dilutive Effects of Authorized Shares**: The reverse stock split will increase the number of authorized but unissued shares, which could be used for dilutive equity financings or to deter takeover attempts without further stockholder action.
• **Financing Risk**: The company expects to require additional financing to fund its ongoing activities, which could lead to further dilution.
• **Credit Agreement Restrictions**: Restrictions on paying cash bonuses to employees/executives in 2024 and 2025 without OFA's consent, and increasing cash compensation for certain senior officers in 2025, could impact talent retention and motivation.
• **Clinical Trial and Revenue Risks**: Performance-based equity awards for NEOs are tied to securing additional funding, initiating Serenity and Tranquility trials, progress towards IGALMI revenues ($5 million), and securing a partnership deal, indicating these are critical, unachieved objectives.

Future Outlook

The company is proactively seeking stockholder approval for a reverse stock split to provide flexibility in addressing potential future non-compliance with Nasdaq's minimum bid price requirements, although it is currently compliant. The Board will determine the exact ratio and timing within 12 months of approval, only if deemed necessary. Performance-based equity awards for executives are tied to future milestones including securing additional funding, initiating clinical trials for Serenity and Tranquility programs, achieving $5 million in IGALMI revenues, and securing a partnership deal, indicating these are key strategic objectives. The company expects to require additional financing for ongoing activities.

Management Comments

• "On behalf of the Board of Directors, I cordially invite you to attend the 2025 annual meeting of stockholders..." (Peter Mueller, Ph.D., Chairman of the Board)
• "On behalf of the Board of Directors and management, it is my pleasure to express our appreciation for your continued support." (Peter Mueller, Ph.D., Chairman of the Board)
• "The Company is currently in compliance with the minimum bid price requirements of the Nasdaq Capital Market and is submitting this proposal as a precautionary measure to provide additional flexibility to address any potential future deficiency with respect to the Nasdaq minimum bid price requirements."
• "We believe that our compensation programs and policies for the year ended December 31, 2024 were an effective incentive for the achievement of our goals, aligned with stockholders interest and worthy of stockholder support."
• "The Board decided to grant PSUs during 2024 in order to further align the interests of Dr. Mehta, Mr. Rodriguez and Mr. Steinhart with the strategic clinical and operational objectives of the Company."

Industry Context

The biopharmaceutical industry is highly capital-intensive, often requiring significant funding for drug discovery, clinical trials, and commercialization. Companies in this sector frequently face challenges in maintaining stock exchange listing requirements, especially smaller firms or those in early development stages. The need for BioXcel Therapeutics to seek approval for a reverse stock split, even as a precautionary measure, highlights the volatile nature of biotech stock prices and the importance of maintaining Nasdaq listing for access to capital and market visibility. The company's focus on securing additional funding, advancing clinical trials (Serenity, Tranquility), and achieving product revenues (IGALMI) aligns with typical growth strategies in the biopharma space. The engagement of compensation consultants and the adoption of clawback policies reflect evolving corporate governance standards across industries, including biotech.

Comparison to Industry Standards

• The company's significant net losses and drastic decline in Total Shareholder Return (TSR) over the past three years suggest underperformance compared to successful biopharmaceutical companies that are effectively advancing products through clinical stages or achieving substantial revenue growth.
• The proposed reverse stock split, while a common tool for Nasdaq compliance, can be viewed negatively by investors and is often a sign of a company struggling to maintain its share price, unlike more robust industry peers.
• The executive compensation structure, including performance-based restricted stock units tied to specific clinical and commercial milestones (e.g., $5M IGALMI revenues, Serenity/Tranquility trials, partnership deals), is standard for biopharma companies, aiming to align executive incentives with critical development and commercial objectives. However, the board's decision to not award 2024 annual bonuses and the negative 'Compensation Actually Paid' figures for executives in 2023 and low figures in 2024 indicate that performance targets were likely not met, or the company faced significant financial headwinds, which is worse than industry standards for well-performing companies.
• The company's reliance on registered direct offerings and other offerings for financing is typical for a development-stage biopharma company, but the frequency and the reduction in warrant exercise prices suggest ongoing capital needs and potentially less favorable financing terms compared to more established or successful peers.

Management Changes

Corporate Governance

Related Party Transactions

• March 2024 Registered Direct Offering: Involved the issuance and sale of common stock, pre-funded warrants, and accompanying warrants. Net proceeds were approximately $24.9 million. The exercise price of warrants to purchase 538,728 shares of common stock was reduced to $9.136 per share on November 21, 2024.
• November 2024 Offering: Involved the issuance and sale of common stock, pre-funded warrants, and accompanying warrants to Armistice, with a combined offering price of $7.68 per share.
• BioXcel LLC: Owned approximately 2.21% of the company's outstanding common stock as of October 31, 2025. BioXcel LLC is majority owned and controlled by BioXcel Holdings, Inc., where Vimal Mehta (CEO) is an executive officer and sole board member.
• Amended and Restated Asset Contribution Agreement with BioXcel LLC (effective June 30, 2017, amended November 7, 2017): The company acquired rights to BXCL501, BXCL701, BXCL502, and BXCL702 candidates for 592,500 shares of common stock and potential milestone payments. No payments were made under these provisions in 2023 or 2024.
• Amended and Restated Separation and Shared Services Agreement with BioXcel LLC (dated June 30, 2017): BioXcel LLC provides drug discovery, chemical, manufacturing, controls, and general and administrative support services. Service charges were $1.3 million for both the years ended December 31, 2024, and 2023.
• Option for Collaborative Services Agreement with BioXcel LLC: The company paid BioXcel LLC $18,000 per month from March 13, 2023, to December 31, 2024, for an option to enter a collaborative services agreement utilizing EvolverAI, with potential low, single-digit royalties and milestone payments.

Stakeholder Impact

• **Shareholders**: Face potential dilution from future financing, risk of stock price decline post-reverse split, and potential loss of stockholder status for those with very few shares. The significant decline in TSR indicates negative impact on shareholder value.
• **Employees/Executives**: No annual cash bonuses for 2024 performance, and restrictions on cash bonuses for 2024 and 2025, could impact morale and retention. Equity awards are tied to challenging performance metrics.
• **Creditors**: The need for additional financing and restrictions on cash bonuses (requiring OFA's consent) suggest the company is managing its financial obligations carefully, potentially under covenants from existing creditors.
• **Customers**: Not directly impacted by governance or financing proposals, but the progress of clinical trials and commercialization of products like IGALMI will eventually affect patient access and market presence.

Next Steps

• Stockholders are to vote on the proposals at the Annual Meeting on December 12, 2025.
• If approved, the Board will have discretion to implement a reverse stock split within 12 months if necessary to regain Nasdaq minimum bid price compliance.
• The Compensation Committee will consider the outcome of the Say-on-Pay vote when making future executive compensation decisions.
• The next say-on-pay advisory vote will occur at the 2026 annual meeting of stockholders.
• The company expects to require additional financing to fund its ongoing activities.
• Executives' performance-based equity awards are tied to initiating Serenity and Tranquility program trials, progressing towards data readouts, achieving $5 million in IGALMI revenues, and securing a partnership deal.

Key Dates

Recommendation

The company faces significant financial challenges, evidenced by substantial net losses and a drastic decline in Total Shareholder Return (TSR) over the past three years. The proposal for a reverse stock split, even if precautionary, highlights underlying concerns about maintaining Nasdaq listing, which is a critical indicator of financial stability. The lack of executive bonuses for 2024 performance and restrictions on future cash bonuses suggest operational underperformance and financial constraints. While capital raises have occurred, the company explicitly states it will require *additional* financing, implying further dilution risk. The overall financial trajectory and governance signals point to a high-risk investment with a strong likelihood of continued value erosion.

Keywords

BioXcel Therapeutics, BTAI, Proxy Statement, Annual Meeting, Reverse Stock Split, Nasdaq Compliance, Executive Compensation, Corporate Governance, Director Election, Auditor Ratification, Biopharmaceutical, Drug Discovery, Clinical Trials, BXCL501, BXCL701, IGALMI, Equity Financing, Shareholder Vote